Pulmonary complications constitute the major cause of morbidity and mortality in the setting of hematopoietic stem cell transplantation. 1 Although infection is the most prevalent etiology, predominantly occurring during the first 3 months post transplantation, noninfectious etiologies have to be considered. Experimental evidence suggests that antithymocyte globulin (ATG) may be toxic for the lung. 2 ARDS or other pulmonary drug-induced toxicities were potentially attributed to ATG in organ transplant recipients 3, 4 or in patients with aplastic anemia. 5 We report a case of potential ATG-associated acute respiratory distress occurring during the conditioning regimen for a bone marrow transplantation.
A 57-year-old women with CML in first CP was admitted for a bone marrow transplantation from her HLA genoidentical sister. She was diagnosed 11 years before with breast cancer which was treated by surgery and radiotherapy. Because pretransplant chest X-rays revealed a small nodule at the left apex, a thoracic CT scan was performed which disclosed that the nodule had irregular shape and limits, and was compatible with pulmonary tuberculosis sequelae. Pulmonary function tests were not performed and a pretransplant echocardiogram was considered as normal. The patient was planned to receive cyclophosphamide 30 mg/kg/day on days −6 and −5 prior to transplant combined with fractionated TBI 2 Gy on 3 consecutive days. Rabbit ATG 2.5 mg/kg/day (Imtix-Sangstat, Lyon, France) from day −7 to day −4 prior to transplant was used as graft rejection prophylaxis. Other medication included ganciclovir, fluconazole, heparin, urate-oxidase and granisetron. A test dose of 1/10 of the full-dose ATG was administered over 1 h and did not induce any adverse reaction. Despite prophylactic use of antihistamines and methylprednisolone 1 mg/kg to improve the tolerance of ATG, fever occurred during the first ATG infusion and was treated with ciprofloxacine and netilmicine. On the 4th day of conditioning regimen (12 h after the third dose of ATG) the patient developed non-febrile dyspnea and hypotension. Hematological values showed a WBC count within normal range (8.9 × 10 9 /l) and platelets slightly decreased to 100 × 10 9 /l. Arterial blood gas measurements drawn on nasal oxygenotherapy revealed severe hypoxemia (PO 2 = 64 mmHg). Chest radiograph exhibited a diffuse reticulonodular pattern. A bronchoalveolar lavage was performed on the following day and showed no evidence of bacterial, mycobacterial, fungal, viral or parasitic infection. Cytologic examination of the fluid showed intra-alveolar hemorrhage. ATG and the transplantation procedure were stopped after the third dose of ATG and antiviral and antimycobacterial agents were added to empirical antibiotics for a possible occult infection. The patient's clinical and radiological status rapidly improved with resolution of all symptoms within a week. She subsequently refused transplantation.
Because multiple causes have to be considered in our patient, it is impossible to definitely prove that the pulmonary symptoms were related to ATG. No infectious cause was found, which does not rule out occult infection. Lung toxicity, as a potential consequence of cyclophosphamide use has been documented in only a few reports, 6 due to the presence of many confounding factors such as concomitant use of other cytotoxic agents, opportunistic infections, pulmonary malignant involvement or potential complications of radiation and oxygen therapy. Two patterns of cyclophosphamide-induced lung toxicity have been described: the early and the late-onset pneumonitis. Symptoms usually occur within 1 to 6 months after a prolonged or repetitive exposure to the drug. Our patient had received cyclophosphamide on 2 consecutive days and the interval between completion of the drug and onset of respiratory signs was less than 24 h which does not square with the usual description of the literature. Therefore, we believe that cyclophosphamide played no consistent role. The symptomatology rapidly resolved after ATG had been withdrawn and despite continuation of all other medication, which rules out the involvement of these drugs. As in our report, ATG has previously been incriminated in the onset of pulmonary druginduced toxicity on the simple grounds that no other cause could be documented. In one patient, rechallenge with ATG resulted in recurrence of clinical and radiographic signs and therefore strongly supported the involvement of that drug.
5
Pathophysiological mechanisms of ATG lung toxicity remain unclear. They may include administration of cytotoxic antibodies, as has been observed following the administration of OKT3 antibodies; complement-dependent lung toxicity as suggested by animal models and administration of leukoagglutinating and lymphocytotoxic antibodies as seen in transfusion-related lung injury. Because ATG is frequently used in the setting of hematopoietic stem cell transplantation, clinicians should be aware that pulmonary complications may represent a very rare side-effect of ATG therapy. 
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Safety profile of mycophenolate mofetil: a response
Drs Basara and Fauser's thoughful and insightful comments 1 reinforce what we have documented in our report, namely that mycophenolate mofetil (MMF) can be safely used for the treatment of chronic GVHD with few sideeffects occurring in a minority of the patients. 2 In our study, adverse gastrointestinal events including diarrhea, nausea and vomiting were the most common clinically relevant side-effects, occurring in 30% (five out of 15) of the patients, whereas severe liver toxicity occurred in one case. Nevertheless, it should be emphasized that MMF was discontinued in only two patients (13%) due to the presence of adverse reactions.
The frequency of gastrointestinal side-effects in our series was higher than the data already reported by the studies of Basara et al 3 and Mookerjee et al 4 indicating 16% and 19% incidence of gastrointestinal symptoms, respectively. Due to the small number of patients our data must be carefully evaluated with no over-interpretation. However, it is worth recalling that our results refer to the use of MMF in a cohort of pediatric patients (in this respect, the age of the five patients who experienced gastrointestinal symptoms varied from 5 to 8 years). This fact might be relevant because the compliance as well as the tolerability and the safety profile of MMF may be different in children compared with the adults.
In accordance with these speculations, we report our experience in 16 adult patients with hematological malignancies who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) and received MMF as prophylaxis (n = 8) or treatment of chronic GVHD (n = 8). Only two patients (12%) experienced adverse gastrointestinal events and therapy was withheld temporarily in one case; MMF was restarted after the resolution of symptoms with no subsequent recurrence of the side-effect. No liver or hematological toxicities have been observed in this small series of patients. Furthermore, Basara and coworkers have argued that organ involvement by severe GVHD (gastrointestinal tract, liver) and adverse effects of MMF may be overlapping, thereby making difficult any meaningful evaluation of the toxicity profile of the drug. As stated in the discussion, we hypothesized that the patient who showed severe liver toxicity might have chronic GVHD with hepatic involvement (as suggested by histological evaluation of the liver) and this fact might in turn have predisposed to liver abnormalities. This clinical situation seems to be very similar to that depicted by Basara and colleagues. 3 In conclusion, our data have documented a favorable toxicity profile of MMF, even though clinicians should be aware that children might have a higher incidence of adverse events with gastrointestinal symptoms predominating. Additional studies are needed to differentiate the sideeffects of MMF from the clinical signs of severe GVHD.
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